You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 27, 2024

Details for Patent: 8,663,683

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,663,683 protect, and when does it expire?

Patent 8,663,683 protects TROKENDI XR and is included in one NDA.

This patent has eleven patent family members in eight countries.

Summary for Patent: 8,663,683

Title:	Sustained-release formulations of topiramate
Abstract:	Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Inventor(s):	Liang; Likan (Boyds, MD), Wang; Hua (Clarksville, MD), Bhatt; Padmanabh P. (Rockville, MD), Vieira; Michael L. (Gaithersburg, MD)
Assignee:	Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:	13/595,103
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,663,683
Patent Claim Types: see list of patent claims	Formulation; Dosage form; Composition; Compound; Use;

Drugs Protected by US Patent 8,663,683

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-001	Aug 16, 2013	AB1	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE	⤷ Sign Up
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-001	Aug 16, 2013	AB1	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF EPILEPSY	⤷ Sign Up
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-002	Aug 16, 2013	AB1	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF EPILEPSY	⤷ Sign Up
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-002	Aug 16, 2013	AB1	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE	⤷ Sign Up
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-003	Aug 16, 2013	AB1	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF EPILEPSY	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,663,683

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007319141	⤷ Sign Up
Canada	2618240	⤷ Sign Up
Germany	07870164	⤷ Sign Up
European Patent Office	1973528	⤷ Sign Up
European Patent Office	2394643	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.